EA034822B9 - Производные n-пиридинилацетамида в качестве ингибиторов сигнального пути wnt - Google Patents

Производные n-пиридинилацетамида в качестве ингибиторов сигнального пути wnt

Info

Publication number
EA034822B9
EA034822B9 EA201790637A EA201790637A EA034822B9 EA 034822 B9 EA034822 B9 EA 034822B9 EA 201790637 A EA201790637 A EA 201790637A EA 201790637 A EA201790637 A EA 201790637A EA 034822 B9 EA034822 B9 EA 034822B9
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
inhibitors
relates
signalling pathway
wnt signalling
Prior art date
Application number
EA201790637A
Other languages
English (en)
Other versions
EA034822B1 (ru
EA201790637A1 (ru
Inventor
Индер Бхамра
Матильда Бингхэм
Ричард Тестар
Луис Саржент
Крейг Донахъю
Original Assignee
РЭДКС ФАРМА ПиЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1417829.7A external-priority patent/GB201417829D0/en
Priority claimed from GBGB1511387.1A external-priority patent/GB201511387D0/en
Application filed by РЭДКС ФАРМА ПиЭлСи filed Critical РЭДКС ФАРМА ПиЭлСи
Publication of EA201790637A1 publication Critical patent/EA201790637A1/ru
Publication of EA034822B1 publication Critical patent/EA034822B1/ru
Publication of EA034822B9 publication Critical patent/EA034822B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)

Abstract

Изобретение относится к соединениям. Конкретно, настоящее изобретение относится к соединениям формулы (III)Более конкретно, настоящее изобретение относится к соединениям, применимым в качестве ингибиторов сигнального пути Wnt. В частности, настоящее изобретение относится к ингибиторам поркупина (Porcn). Кроме того, изобретение относится к способам получения соединений и применениям соединений. Таким образом, соединения по настоящему изобретению могут применяться в лечении состояний, опосредуемых сигнальным путем Wnt, например, для лечения рака, саркомы, меланомы, рака кожи, гематологических опухолей, лимфомы, рака и лейкоза; или повышения эффективности противоракового лечения.
EA201790637A 2014-10-08 2015-10-08 Производные n-пиридинилацетамида в качестве ингибиторов сигнального пути wnt EA034822B9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1417829.7A GB201417829D0 (en) 2014-10-08 2014-10-08 Compounds
GBGB1511387.1A GB201511387D0 (en) 2015-06-29 2015-06-29 Compounds
PCT/GB2015/052939 WO2016055786A1 (en) 2014-10-08 2015-10-08 N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway

Publications (3)

Publication Number Publication Date
EA201790637A1 EA201790637A1 (ru) 2017-10-31
EA034822B1 EA034822B1 (ru) 2020-03-25
EA034822B9 true EA034822B9 (ru) 2020-10-23

Family

ID=54337304

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790637A EA034822B9 (ru) 2014-10-08 2015-10-08 Производные n-пиридинилацетамида в качестве ингибиторов сигнального пути wnt

Country Status (23)

Country Link
US (4) US10047079B2 (ru)
EP (1) EP3204378B3 (ru)
JP (2) JP6722178B2 (ru)
KR (1) KR102525131B1 (ru)
CN (1) CN107108565B (ru)
AU (1) AU2015329784C1 (ru)
CA (1) CA2960446C (ru)
CY (1) CY1122243T1 (ru)
DK (1) DK3204378T6 (ru)
EA (1) EA034822B9 (ru)
ES (1) ES2754349T7 (ru)
HR (1) HRP20191826T4 (ru)
HU (1) HUE046914T2 (ru)
IL (1) IL251131B (ru)
LT (1) LT3204378T (ru)
MX (1) MX2017004637A (ru)
PH (1) PH12017500611A1 (ru)
PL (1) PL3204378T6 (ru)
PT (1) PT3204378T (ru)
SG (1) SG11201701837UA (ru)
SI (1) SI3204378T1 (ru)
WO (1) WO2016055786A1 (ru)
ZA (1) ZA201701842B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204378B3 (en) 2014-10-08 2022-05-25 Redx Pharma PLC N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway
MX2017004639A (es) 2014-10-08 2017-07-17 Redx Pharma Plc Derivados de n-piridinil acetamida como inhibidores de la via de señalizacion wnt.
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
US10793544B2 (en) 2016-09-01 2020-10-06 The Board Of Regents Of The University Of Texas System Disubstituted and trisubstituted 1,2,3-triazoles as Wnt inhibitors
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
JP2019064975A (ja) * 2017-10-03 2019-04-25 国立大学法人 熊本大学 抗がん剤
AU2019215799B2 (en) * 2018-02-01 2022-04-14 The University Of Sydney Anti-cancer compounds
PL3762368T3 (pl) 2018-03-08 2022-06-06 Incyte Corporation ZWIĄZKI AMINOPIRAZYNODIOLOWE JAKO INHIBITORY PI3K-γ
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
IL294052A (en) 2019-12-20 2022-08-01 Tenaya Therapeutics Inc Fluoroalkyl-oxadiazoles and their uses
WO2022094477A1 (en) * 2020-11-02 2022-05-05 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancers having dysregulated wnt signaling pathways
GB202100526D0 (en) 2021-01-15 2021-03-03 Redx Pharma Plc Pharmaceutical formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK86699A3 (en) 1996-12-23 2000-11-07 Du Pont Pharm Co Nitrogen containing heteroaromatics as factor xa inhibitors
ATE236890T1 (de) 1996-12-23 2003-04-15 Bristol Myers Squibb Pharma Co Sauerstoff oder schwefel enthaltende 5-gliedrige heteroaromatishe derivative als factor xa hemmer
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
SE0203654D0 (sv) 2002-12-09 2002-12-09 Astrazeneca Ab New compounds
WO2004071447A2 (en) * 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as therapeutic agents
JP2008515961A (ja) 2004-10-12 2008-05-15 アストラゼネカ アクチボラグ 癌に対する使用のためのキナゾリン誘導体
EP2148865B1 (en) * 2007-04-30 2017-05-17 Genentech, Inc. Pyrazole inhibitors of wnt signaling
EP2231602A1 (en) 2007-12-13 2010-09-29 Amgen, Inc Gamma secretase modulators
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
CN104302782A (zh) * 2012-02-28 2015-01-21 诺华股份有限公司 利用rnf43突变状态选择wnt信号转导抑制剂给药的癌症患者
GB2513403A (en) 2013-04-26 2014-10-29 Agency Science Tech & Res WNT pathway modulators
MX2017004639A (es) 2014-10-08 2017-07-17 Redx Pharma Plc Derivados de n-piridinil acetamida como inhibidores de la via de señalizacion wnt.
EP3204378B3 (en) 2014-10-08 2022-05-25 Redx Pharma PLC N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway

Also Published As

Publication number Publication date
PT3204378T (pt) 2019-11-12
KR20170063906A (ko) 2017-06-08
WO2016055786A1 (en) 2016-04-14
EP3204378A1 (en) 2017-08-16
EA034822B1 (ru) 2020-03-25
CA2960446C (en) 2023-09-19
AU2015329784C1 (en) 2020-10-15
PL3204378T4 (pl) 2020-03-31
CY1122243T1 (el) 2020-11-25
US10793560B2 (en) 2020-10-06
AU2015329784A1 (en) 2017-03-30
LT3204378T (lt) 2019-10-25
ZA201701842B (en) 2022-05-25
ES2754349T3 (es) 2020-04-17
AU2015329784B2 (en) 2019-08-22
CA2960446A1 (en) 2016-04-14
US10047079B2 (en) 2018-08-14
US20180319788A1 (en) 2018-11-08
CN107108565B (zh) 2019-08-23
JP2020090542A (ja) 2020-06-11
US20210046076A1 (en) 2021-02-18
IL251131A0 (en) 2017-04-30
EP3204378B1 (en) 2019-07-10
EA201790637A1 (ru) 2017-10-31
EP3204378B3 (en) 2022-05-25
NZ729820A (en) 2023-09-29
JP2017530183A (ja) 2017-10-12
HRP20191826T4 (hr) 2022-08-05
HUE046914T2 (hu) 2020-04-28
SI3204378T1 (sl) 2019-12-31
US20230365549A1 (en) 2023-11-16
KR102525131B1 (ko) 2023-04-24
US11643408B2 (en) 2023-05-09
HRP20191826T1 (hr) 2020-01-10
BR112017006476A2 (pt) 2017-12-19
SG11201701837UA (en) 2017-04-27
PL3204378T3 (pl) 2020-03-31
DK3204378T6 (da) 2022-07-18
JP6722178B2 (ja) 2020-07-15
MX2017004637A (es) 2017-06-30
DK3204378T3 (da) 2019-10-21
ES2754349T7 (es) 2022-09-19
CN107108565A (zh) 2017-08-29
PH12017500611A1 (en) 2017-09-25
IL251131B (en) 2020-07-30
US20170275276A1 (en) 2017-09-28
PL3204378T6 (pl) 2022-09-12

Similar Documents

Publication Publication Date Title
MX2017004639A (es) Derivados de n-piridinil acetamida como inhibidores de la via de señalizacion wnt.
PH12017500611A1 (en) N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway
CR20190478A (es) Inhibidores de pd-1/pd-l1
PH12017502141A1 (en) Compounds and their methods of use
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
PH12018501268A1 (en) Compounds useful as kinase inhibitors
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
MX2018015657A (es) Compuestos heterociclico como antibacterianos.
AU2015314007B2 (en) Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
SG10201900564WA (en) Methods for treating cancer
MY183327A (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
BR112017026201A2 (pt) inibidores de mir-155 para o tratamento de linfoma cutâneo de células t (ctcl)
SA515370253B1 (ar) مركب أميد عطري غير متجانس الحلقة يحتوي على نتروجين ثنائي الحلقة
WO2015128873A9 (en) "6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors"
GB2553684A8 (en) Ethynylxanthines, preparation and use for cancer treatment

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent